Eli Lilly's weight loss pill succeeds in first late-stage trial on diabetes patients
1. Eli Lilly's obesity pill orforglipron met trial goals for diabetes patients. 2. The pill shows significant weight loss potential, averaging 16 pounds in 40 weeks. 3. 8% of patients discontinued due to mild gastrointestinal side effects. 4. Results missed some analyst estimates for blood sugar reduction metrics. 5. Regulatory approval expected by year-end for obesity; diabetes approval by 2026.